KLAR_BTA fundamentals

Klaria Pharma Holding AB engages in the development and commercialization of pharmaceutical products for migraine and cancer-related pain. Its operation is based on a patented drug delivery platform in an alginate-based polymer film. The firm's project portfolio currently includes various pain states, opioid overdoses, cannabinoids, and allergic shock. The company was founded by Scott Boyer and Fredrik Hübinette in 2015 and is headquartered in Uppsala, Sweden.